Grace Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $2.1 million. The company is currently focused on resubmitting its New Drug Application (NDA) for GTx-104 after addressing CMC and non-clinical items identified by the FDA. Management noted that a recent $10 million financing has extended the company's cash runway through the end of 2028.
“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104.”
Prashant Kohli, Chief Executive Officer
“The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission.”
Grace Therapeutics reported a net loss of $17.9 million for the six months ended September 30, 2026, primarily driven by a $13.5 million impairment of intangible assets related to GTx-102 and GTx-101. The company strengthened its liquidity through a $9.2 million private placement in August 2026, providing sufficient cash to fund operations for at least 12 months.
Grace Therapeutics Insider Opaleye Management Inc. Buys $18.5K of Stock
Opaleye Management Inc. bought 10,328 shares of Grace Therapeutics, Inc. at $1.79 a share, worth $18.5K in total on Nov 3, 2026. Shares held after the trade: 3,046,739 (+0.3%).
Grace Therapeutics Insider Opaleye Management Inc. Buys $159K of Stock
Opaleye Management Inc. bought 87,801 shares of Grace Therapeutics, Inc. at $1.77 to $1.93 a share (average $1.81) in 2 transactions, worth $159K in total between Oct 22, 2026 and Oct 26, 2026. Shares held after the trade: 3,036,411 (+2.2%).